LENSAR Inc. is a commercial-stage medical device company. It focuses on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. LENSAR Inc. is based in Orlando, Florida.
| Revenue (Most Recent Fiscal Year) | $53.49M |
| Net Income (Most Recent Fiscal Year) | $-31.40M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.43 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -84.49% |
| Net Margin (Trailing 12 Months) | -84.49% |
| Return on Equity (Trailing 12 Months) | -737.30% |
| Return on Assets (Trailing 12 Months) | -72.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.03 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.42 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 11.94M |
| Free Float | 4.06M |
| Market Capitalization | $141.90M |
| Average Volume (Last 20 Days) | 0.05M |
| Beta (Past 60 Months) | 0.49 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 66.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 40.15% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |